Functional Genomics Link REST to Endothelial Plasticity and Atherosclerosis

Circ Res. 2025 Nov 26. doi: 10.1161/CIRCRESAHA.125.326628. Online ahead of print.ABSTRACTBACKGROUND: Genome-wide association studies have identified multiple novel loci that contribute to coronary artery disease pathogenesis, but the mechanisms of these associations remain largely unknown.METHODS: I

M Maria Viskadourou

Insulin Resistance and Blood Pressure Control on Cognitive Outcomes

Hypertension. 2025 Nov 26. doi: 10.1161/HYPERTENSIONAHA.125.24666. Online ahead of print.ABSTRACTBACKGROUND: The influence of IR (insulin resistance) on the response of patients with hypertension to intensive systolic blood pressure treatment in terms of cognitive performance remains unclear, as doe

C Chenyu Fan

Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists

Cureus. 2025 Nov 23;17(11):e97588. doi: 10.7759/cureus.97588. eCollection 2025 Nov.ABSTRACTBACKGROUND: Steroidal mineralocorticoid receptor antagonists (MRAs) reduce morbidity in heart failure (HF) but frequently cause hyperkalemia, limiting long-term use. Non-steroidal MRAs such as finerenone offe

A Ayoyimika O Okunlola

COVID-19-Induced Left Atrial Appendage Thrombus

Cureus. 2025 Oct 24;17(10):e95303. doi: 10.7759/cureus.95303. eCollection 2025 Oct.ABSTRACTLeft atrial appendage (LAA) thrombus formation is a clinically significant complication that can occur in patients with atrial fibrillation (AF), particularly in the setting of coexisting conditions that affec

S Steven Douedi

Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial

Front Immunol. 2025 Nov 10;16:1687344. doi: 10.3389/fimmu.2025.1687344. eCollection 2025.ABSTRACTBACKGROUND: Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) exhibit a dismal prognosis, occurring in 44%-62.2% of cases at initial diagnosis. The optimal treatment for this

N Ning Mo